XUANZHUBIO-B

We are a Sino Biopharm company driven by innovation and a global perspective. With a deep understanding of the Chinese pharmaceutical industry and deep insight into its unique clinical needs, we make patients healthier and live better lives. Since our establishment in 2008, we have established a comprehensive in-house R&D platform to support our development of highly competitive and balanced pipelines. As of the last practical date, we have more than ten drug assets under active development, covering digestive diseases, tumors, and nonalcoholic steatohepatitis (NASH). We are committed to addressing critical medical needs and are supported by three core technology platforms (i.e. small molecule drug development platform, biopharmaceutical R&D platform, and clinical development platform). These proprietary platforms are built on our deep small molecule drug and biologics development expertise and are the foundation for our discovery and development of innovative medicines. These platforms are designed to cover the entire development process of various drug models, work collaboratively, and achieve valuable cross-functional synergy at critical stages of drug development.